https://orcid.org/0000-0003-3817-6696
References
- Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370–379.
- Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83(1):46–52.
- Napolitano M, Fabbrocini G, Genco L, et al. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. J Eur Acad Dermatol Venereol. 2022;36(9):1497–1498.
- Martora F, Scalvenzi M, Ruggiero A, et al. Hidradenitis suppurativa and JAK inhibitors: a review of the published literature. Medicina. 2023;59(4):1.
- Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165–1173.
- Jiang W, Ma X, Guo T,et al. Abrocitinib-A promising option for patients with refractory bullous pemphigoid. J Eur Acad Dermatol Venereol. 2023;38(1):e119–21.
- Burningham KM, Cao J, Dominguez AR. Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate. JAAD Case Rep. 2022;27:67–69.
- James H, Paley GL, Brasington R, et al. Tofacitinib for refractory ocular mucous membrane pemphigoid. Am J Ophthalmol Case Rep. 2021;22:101104.
- Juczynska K, Wozniacka A, Waszczykowska E, et al. Expression of the JAK/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis. Med Inflamm. 2017;2017:6716419.
- Ciechanowicz P, Rakowska A, Sikora M, et al. JAK-inhibitors in dermatology: current evidence and future applications. J DermatolTreat. 2019;30(7):648–658.